AU2007290277B2 - Use of tenecteplase for treating acute ischemic stroke - Google Patents

Use of tenecteplase for treating acute ischemic stroke Download PDF

Info

Publication number
AU2007290277B2
AU2007290277B2 AU2007290277A AU2007290277A AU2007290277B2 AU 2007290277 B2 AU2007290277 B2 AU 2007290277B2 AU 2007290277 A AU2007290277 A AU 2007290277A AU 2007290277 A AU2007290277 A AU 2007290277A AU 2007290277 B2 AU2007290277 B2 AU 2007290277B2
Authority
AU
Australia
Prior art keywords
tenecteplase
stroke
bolus
minutes
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007290277A
Other languages
English (en)
Other versions
AU2007290277A1 (en
Inventor
Peter Kuebler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007290277(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2007290277A1 publication Critical patent/AU2007290277A1/en
Application granted granted Critical
Publication of AU2007290277B2 publication Critical patent/AU2007290277B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2007290277A 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke Active AU2007290277B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
US60/823,868 2006-08-29
PCT/US2007/074997 WO2008027687A2 (en) 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke

Publications (2)

Publication Number Publication Date
AU2007290277A1 AU2007290277A1 (en) 2008-03-06
AU2007290277B2 true AU2007290277B2 (en) 2013-04-11

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007290277A Active AU2007290277B2 (en) 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke

Country Status (21)

Country Link
US (2) US20080107641A1 (enExample)
EP (1) EP2056856B1 (enExample)
JP (1) JP5785687B2 (enExample)
KR (1) KR20090045405A (enExample)
CN (1) CN101505785A (enExample)
AU (1) AU2007290277B2 (enExample)
BR (1) BRPI0716143A2 (enExample)
CA (1) CA2661012C (enExample)
CO (1) CO6150188A2 (enExample)
EA (1) EA015573B1 (enExample)
EC (1) ECSP099178A (enExample)
IL (2) IL196987A (enExample)
MX (1) MX2009001918A (enExample)
MY (1) MY163119A (enExample)
NO (1) NO342302B1 (enExample)
NZ (1) NZ574767A (enExample)
SG (3) SG10201501498VA (enExample)
TW (1) TWI439282B (enExample)
UA (1) UA97486C2 (enExample)
WO (1) WO2008027687A2 (enExample)
ZA (1) ZA200900957B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US8030350B2 (en) 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
MX2009010988A (es) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
JP2012513812A (ja) * 2008-12-24 2012-06-21 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Ｍｒ卒中検出および処置による心臓介入のシステム、方法および装置
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
JP5762414B2 (ja) * 2009-08-24 2015-08-12 ハフ イヤ インスティテュート 急性音響外傷の治療方法
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
MY171723A (en) * 2010-12-23 2019-10-24 Gennova Biopharmaceuticals Ltd Pharmaceutical compositions of tenecteplase
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
US8715315B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment systems
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
JP6437517B2 (ja) 2013-03-15 2018-12-12 インセラ セラピューティクス，インク． 血管治療装置及び方法
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
MX383595B (es) * 2014-10-21 2025-03-14 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)
CN108697423A (zh) 2016-02-16 2018-10-23 伊瑟拉医疗公司 抽吸装置和锚定的分流装置
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
EP3573635B1 (en) * 2017-01-24 2021-05-12 Ekos Corporation Method for the treatment of thromboembolism
EP3624832B1 (en) * 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (en) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2
MX2022010160A (es) * 2020-02-19 2022-10-10 Nono Inc Tratamiento de combinación de apoplejia con inhibidor de psd-95 escindible por plasmina y reperfusión.
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0786257B1 (en) 1992-06-03 2003-07-30 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STROKE Vol.36, No 3. march 2005, pp 607-612 *

Also Published As

Publication number Publication date
NZ574767A (en) 2012-02-24
HK1131054A1 (en) 2010-01-15
TW200817033A (en) 2008-04-16
NO342302B1 (no) 2018-04-30
WO2008027687A3 (en) 2008-05-22
UA97486C2 (ru) 2012-02-27
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
NO20091296L (no) 2009-05-28
CO6150188A2 (es) 2010-04-20
MX2009001918A (es) 2009-03-06
US9023346B2 (en) 2015-05-05
ZA200900957B (en) 2010-05-26
WO2008027687A2 (en) 2008-03-06
BRPI0716143A2 (pt) 2013-11-26
MY163119A (en) 2017-08-15
TWI439282B (zh) 2014-06-01
JP5785687B2 (ja) 2015-09-30
US20080107641A1 (en) 2008-05-08
EA200970237A1 (ru) 2009-08-28
CA2661012A1 (en) 2008-03-06
IL196987A0 (en) 2011-08-01
KR20090045405A (ko) 2009-05-07
EP2056856B1 (en) 2015-01-14
US20120164157A1 (en) 2012-06-28
SG174753A1 (en) 2011-10-28
EP2056856A2 (en) 2009-05-13
JP2010502629A (ja) 2010-01-28
IL248176A0 (en) 2016-11-30
SG10201501498VA (en) 2015-04-29
CN101505785A (zh) 2009-08-12
AU2007290277A1 (en) 2008-03-06
EA015573B1 (ru) 2011-10-31
CA2661012C (en) 2019-03-19
SG10201804944XA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
AU2007290277B2 (en) Use of tenecteplase for treating acute ischemic stroke
Barreto Intravenous thrombolytics for ischemic stroke
US10864257B2 (en) Method for prevention or treatment of acute and chronic thrombosis
US20200255530A1 (en) Compositions and methods for treatment of stroke and other cns disorders
EP2845601B1 (en) Composition for use for dissolving thrombi
Xu et al. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment
Broderick Recanalization therapies for acute ischemic stroke
HK1131054B (en) Use of tenecteplase for treating acute ischemic stroke
EP2289542A1 (en) Treatment of neurological or neurodegenerative disorders
Brott Reopening occluded cerebral arteries
Clark et al. Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents
Spinler et al. Update on strategies to improve thrombolysis for acute myocardial infarction
Weiner Thrombolytic agents in critical care
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
Diaz-Ricart Desmoteplase
KR100831770B1 (ko) ｔ-ＰＡ 변이체와 저분자량 헤파린의 조합 치료
Hoang et al. The efficacy and safety of tissue plasminogen activator in acute ischemic strokes
WO2009046742A1 (en) Staphylokinase variant
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
KR20210014024A (ko) 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법
Zhang et al. Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice
AHN et al. Recombinant Factor VIIa Treatment for Acute Intracerebral Hemorrhage
WO2007134813A2 (en) Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism
Walsh Tissue Plasminogen Activator-Based Thrombolytic Agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)